Lifeline Biotechnologies' First Warning Systems Updates Website

RENO, Nev., March 12, 2012 /PRNewswire/ -- Lifeline Biotechnologies, Inc., (Pink Sheets: LLBO) announces its subsidiary, First Warning Systems, Inc. (FWS) has updated its website: firstwarningsystems.com. Information on the status and the progress of the Company is available on this site.

Jim Holmes, Lifeline's CEO said, "FWS's website is a comprehensive source of Company information and we plan to have continuous updates posted there.  We are moving forward on our plans to update the FWS detection device and to automate our predictive bioinformatics algorithms.  Our management team has been expanded to assist in accelerating the completion of development for final testing.  Our focus is an FDA medical device marketing clearance submission, possibly as early as 2013."  

About Lifeline Biotechnologies

Lifeline Biotechnologies, Inc. (OTC Market: LLBO) founded in 1994 is based in Reno, NV.  The Company has invested over $10M in a device and process for early detection of breast tissue abnormalities some of which are cancerous or pre-cancer.  Three patents are pending, one patent is issued and three clinical trials with over 650 participants have been completed confirming "Proof of Concept."  www.lbti.com

About First Warning Systems

First Warning Systems, (FWS) founded in 2008, based in Reno, NV is a subsidiary of Lifeline Biotechnologies, Inc. (LLBO).  FWS holds the exclusive development, marketing and manufacturing licenses to commercialize LLBO's intellectual property for the FWS product line. The FWS product line is a device and process for early detection of breast tissue abnormalities that lead to health risk assessment and management.  Three clinical trials with over 650 participants have achieved superior outcomes when compared to other diagnostic protocols.  FWS is planning a final, limited clinical trial and a 510(k) device classification to validate the fourth generation of the FWS product.  www.firstwarningsystems.com

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, the ability to obtain financing, successful development of the Company's product or market acceptance of the product and regulatory and shareholder approval for anticipated actions.

For more information, contact:

Jim Holmes, CEO 775-852-3222

Email: [e-mail]

 

SOURCE Lifeline Biotechnologies, Inc.

Copyright 2012 PR Newswire